Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson's Disease

被引：16

作者：

Hu, Xinyu ^{[1
]}

Li, Jingwen ^{[1
]}

Wang, Xinyi ^{[1
]}

Liu, Hanshu ^{[1
]}

Wang, Tao ^{[1
]}

Lin, Zhicheng ^{[2
]}

Xiong, Nian ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China

[2] Harvard Med Sch, McLean Hosp, Lab Psychiat Neurogenom, Belmont, MA 02478 USA

来源：

ANTIOXIDANTS | 2023年 / 12卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Parkinson's disease; melatonin; sleep disorders; mechanisms; clinical trials; EXCESSIVE DAYTIME SLEEPINESS; RESTLESS LEGS SYNDROME; BEHAVIOR DISORDER; DOUBLE-BLIND; EXOGENOUS MELATONIN; ALPHA-SYNUCLEIN; CONTROLLED-TRIAL; LIGHT THERAPY; MODEL; APNEA;

D O I：

10.3390/antiox12020396

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Parkinson's disease (PD) is a complex, multisystem disorder with both neurologic and systemic manifestations, which is usually associated with non-motor symptoms, including sleep disorders. Such associated sleep disorders are commonly observed as REM sleep behavior disorder, insomnia, sleep-related breathing disorders, excessive daytime sleepiness, restless legs syndrome and periodic limb movements. Melatonin has a wide range of regulatory effects, such as synchronizing circadian rhythm, and is expected to be a potential new circadian treatment of sleep disorders in PD patients. In fact, ongoing clinical trials with melatonin in PD highlight melatonin's therapeutic effects in this disease. Mechanistically, melatonin plays its antioxidant, anti-inflammatory, anti-excitotoxity, anti-synaptic dysfunction and anti-apoptotic activities. In addition, melatonin attenuates the effects of genetic variation in the clock genes of Baml1 and Per1 to restore the circadian rhythm. Together, melatonin exerts various therapeutic effects in PD but their specific mechanisms require further investigations.

引用

页数：23

共 50 条

[41] Sleep disorders in Parkinson's disease: An overview
Comella, Cynthia L.
MOVEMENT DISORDERS, 2007, 22 : S367 - S373
[42] Sleep disorders in patients with Parkinson's disease
Martinez Martin, Pablo
Rodriguez Blazquez, Carmen
SALUD I CIENCIA, 2009, 17 (01): : 25 - 28
[43] Actigraphic assessment of the effect of melatonin treatment on nighttime sleep in patients with Parkinson's disease
Dowling, GA
Mastick, J
Colling, E
Carter, J
Aminoff, MA
SLEEP, 2003, 26 : A331 - A331
[44] Impulse control disorders in Parkinson's disease are associated with increased sleep disturbance
O'Sullivan, S. S.
Loane, C. M.
Lawrence, A. D.
Evans, A. H.
Piccini, P.
Lees, A. J.
MOVEMENT DISORDERS, 2009, 24 : S395 - S395
[45] Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam
Litvinenko, I. V.
Krasakov, I. V.
Tikhomirova, O. V.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (12) : 26 - +
[46] 672 ASSESSMENT OF THERAPEUTIC RESPONSE TO MELATONIN IN PARKINSON'S DISEASE PATIENTS WITH SLEEP DISORDERS, A QI PROJECT
Melrose, R.
Kershaw, C.
Jones, E.
AGE AND AGEING, 2022, 51
[47] Sleep disorders in Parkinson's disease and other movement disorders
Clavero, P.
Rodriguez-Oroz, M. C.
ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2007, 30 : 143 - 153
[48] Sleep disorders in Parkinson's disease without dementia: A comparative randomized controlled study of melatonin and clonazepam
Krasakov, I. V.
Litvinenko, I. V.
MOVEMENT DISORDERS, 2014, 29 : S294 - S294
[49] Sleep architecture in Parkinson's disease and Parkinson's disease associated dementia
Sousa, L.
Laranjinha, I.
Lopes, J.
Ramalheira, J.
da Silva, A. M.
Lima, A. B.
Magalhaes, M.
MOVEMENT DISORDERS, 2017, 32
[50] Parkinson's disease:: proteome and effect of neuroprotective drugs
Mandel, S. A.
Riederer, P.
Gruenblatt, E.
Youdim, M. B. H.
AMINO ACIDS, 2007, 33 (03) : XXIV - XXIV

← 1 2 3 4 5 →